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ORALLY-DOSED CITALOPRAM STIMULATES SMALL INTESTINAL MUCOSAL 
GROWTH 
Lucy Zhang, Chasen J. Greig, and Robert A. Cowles. Section of Pediatric Surgery, 
Department of Surgery, Yale University, School of Medicine, New Haven, CT, USA. 
 
 
Parenterally-administered selective serotonin reuptake inhibitors (SSRI), such as 
citalopram, increase intestinal mucosal absorptive surface by day 7 of treatment. We 
hypothesized that enteral citalopram would also induce intestinal mucosal growth, thus 
allowing for therapy with an oral agent. In the study’s first phase, C57BL/6 mice 
received peanut butter (PB) pellets containing 10, 50, or 100 mg/kg/day citalopram for 7 
days; or 25 mg/kg/day citalopram for 14 or 21 days; or plain PB pellets for 7, 14, or 21 
days. In the second phase, C57BL/6 mice received 0, 10, 25, or 50 mg/kg/day 
citalopram in drinking water for 2, 3, 6, or 8 weeks, or for 6 weeks followed by 2 weeks 
of drug withdrawal. Two-centimeter ileal segments were harvested and prepared for 
microscopic assessment of villus height (VH), crypt depth (CD), villus width (VW), and 
crypt width (CW). Mucosal surface area (MSA) was calculated and data were compared 
using Student’s t-test. Enteral citalopram given for 14 days in PB pellets resulted in an 
increased VH (p <0.0001), VW (p = 0.0058), and ileal MSA per mm2 (p = 0.0007). The 
increase in MSA was sustained at 21 days (p <0.0001). When citalopram was given in 
drinking water, VH was greater than controls by week 3 (p <0.0001 across all three 
doses); however, MSA per mm2 was not significantly increased, regardless of treatment 
dose or duration. Further work is needed, but SSRIs show some promise in the short-
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So find something new to try, something to change. Count how often you succeed and how often 
you fail. Write about it. Ask people what they think. See if you can keep the conversation going. 








1.1. Short Bowel Syndrome and Intestinal Failure 
In 1968, Wilmore and Dudrick revolutionized the care of children with short bowel 
syndrome (SBS) when they described the first such infant to grow and gain weight while 
receiving only intravenous parenteral nutrition (PN) over the course of over 6 weeks (2). 
She had undergone major bowel resection for intestinal atresia, and shortly after the 
operation, developed a functional intestinal obstruction. Despite receiving intravenous 
fluids containing plasma, glucose, and protein, she continued to lose significant weight 
and deteriorate in condition. At that point, the decision was made to initiate PN. Within 
24 hours, she was noticeably resuscitated, and by day 45, her remaining bowel had 
adapted sufficiently to allow for tolerance of full enteral nutrition (2). 
 Fifty years later, PN remains a mainstay of SBS treatment, yet the outcomes are 
poor. Any investigation into better treatments for SBS, however, first requires an 
understanding of SBS. 
 
1.1.1. Definition and Epidemiology 
SBS is characterized by malabsorption that stems from major loss of small intestinal 
surface area, typically due to surgical resection or congenital disease, and can affect both 
children and adults (3). The most common etiologies in the neonatal and young 
pediatric populations are necrotizing enterocolitis and intestinal anomalies, such as 
midgut volvulus, gastroschisis, Hirschsprung disease, and as Wilmore and Dudrick 
encountered, intestinal atresia (3-5). Among older children and adults, SBS is more often 





SBS is the most common cause of intestinal failure (IF), which is a blanket term used to 
describe a condition of grossly insufficient nutrient absorption resulting in not only an 
inability to support homeostasis or growth, but also a dependence on PN. Causes of IF 
that are not associated with shortened bowel length include disorders of intestinal 
motility as well as congenital enteropathies (3, 6). 
Given the lack of a consensus definition for SBS/IF, however, considerable 
variability exists in the incidence of SBS/IF that is reported in the literature. One 
retrospective cohort study found that, at their institution, the incidence of newborns 
with SBS was 353.7 cases per 100,000 live births in preterm infants and 3.5 per 100,000 in 
term infants, for an overall rate of 24.5/100,000 (3, 7). Other studies have found SBS 
incidence rates of 700 and 1200 per 100,000 live births, among neonates weighing less 
than 1500 grams (4, 6, 8, 9). 
Despite many advances in treatment options over the past 50 years since PN was 
introduced for SBS/IF, the outcomes are still devastating. Several factors, including 
length of remaining small bowel (less than 50 cm), the absence of intact colon and/or 
ileocecal valve, older patient age, and dependence on PN, portend a poorer prognosis. 
Mortality rates range consistently from approximately 10% to 30% (4-6, 10-15). 
 
1.1.2. Economics 
The economic impact of SBS/IF is almost as staggering. One study, adjusted for inflation 
to the year 2005, found that the total cost of care for patients with SBS in the first five 
years after diagnosis was on average more than 1.6 million US dollars, with the first year 
typically costing a little over $500,000 and years 2-5 costing roughly $250,000 to $300,000 





majority of this cost, especially in the first few years after diagnosis. As the years went 
by, patients spent progressively less and less time in the hospital, and this was reflected 
in the costs of care: in-hospital expenses shrank from over $400,000 in the first year to 
less than $50,000 in the fifth year, while home care costs more than doubled from less 
than $90,000 in the first year to almost $185,000 by year 5 (5). PN was the predominant 
home care expense, even as most patients were eventually able to wean off of it. The 
categories of “antimicrobials,” “injectables,” “intravenous hydration,” and “enteral 
nutrition” additionally contributed to home costs (5). These data clearly suggest that 
SBS/IF is a costly and morbid disease that warrants aggressive study. 
 
1.1.3. Intestinal Adaptation and Complications 
Much of the morbidity of SBS/IF derives from the disease process itself as well as 
sequelae of the treatment, which begs the need for investigation into better treatment 
options. In response to major resection, the intestine gradually undergoes changes to 
compensate for the reduced absorptive surface and capacity. This process, termed 
“intestinal adaptation,” includes gastric hypersecretion, small bowel dilatation, and, to 
some extent, lengthening, as well as increases in villus height and crypt depth at the 
microscopic level (6, 11, 12). These changes are thought to occur in an attempt to restore 
mucosal surface area that was lost due to resection. 
Fifty percent of patients who ultimately wean from PN to enteral autonomy do 
so within the first 6 months, and 95% are able to be free from PN within 2 years (11, 13). 
However, those most severely affected patients who require long-term PN, or those who 






Malabsorptive diarrhea is one such symptom that plagues patients with SBS/IF, 
and can precipitate fluid and electrolyte imbalances. Furthermore, the major resection of 
small bowel prevents the absorption of vitamins and minerals, particularly vitamin B12, 
zinc, magnesium, calcium, and the fat-soluble vitamins A, D, E, K, and has been shown 
to remove an inhibitory mechanism and trigger hypergastrinemia, hyperacidity, and 
peptic ulcer occurrence (4, 11). Ileal resection disrupts the enterohepatic circulation of 
bile acids, which not only contributes to fat malabsorption and both secretory diarrhea 
and steatorrhea in patients with SBS, but also cholelithiasis and calcium oxalate 
nephrolithiasis (11). 
Small intestinal bacterial overgrowth (SIBO) is another common consequence of 
the changes in intestinal anatomy, motility, and secretion associated with SBS (6, 16). Of 
note, the bacteria Lactobacilli can cause D-lactic acidosis in patients with an intact colon, 
by fermenting carbohydrates into D-lactic acid, which is then absorbed in the colon. The 
condition is characterized by mental status changes and an anion gap metabolic acidosis 
that is unexplained because laboratory tests typically measure for the L-lactic acid 
stereoisomer (11). 
While myriad issues arise from the malabsorption and intestinal resection of 
SBS/IF, another considerable set of complications stems from the use of PN. Central 
venous access carries its own substantial risks: catheter breakage, thrombosis, infection, 
and sepsis (4). Ethanol lock therapy, in which 70% ethanol is infused into the catheter 
during off-cycles of PN, seems to be effective in reducing the number of central catheter-
associated bloodstream infections; however, there is evidence to suggest that ethanol 





reduced bone mineral density and metabolic bone disease, in the form of osteomalacia 
or osteoporosis, has been found in up to 84% of patients receiving PN (11, 20). 
Arguably the most notorious and potentially fatal complication, however, is 
intestinal failure-associated liver disease (IFALD). IFALD can lead to steatosis, 
cholestasis, fibrosis, and even cirrhosis, and affects up to 40-60% of infants on PN (4, 11, 
21-23). Furthermore, a strong correlation has been found between SBS mortality and 
IFALD. One study found that Kaplan-Meier survival was less than 20% among children 
with cholestasis; in those without cholestasis, survival was closer to 80% (4, 24). Thus, 
minimizing the need for PN and maximizing functional intestinal surface area and 
intestinal motility are important goals in the treatment of patients with SBS/IF. 
 
1.1.4. Treatment 
Both SBS and IF are complex conditions that require long-term care from multiple 
disciplines, whether nutritional, surgical, medical, or some combination of the three. 
Notably, intestinal rehabilitation programs have been developed worldwide to more 
easily coordinate care for these complex patients, and these efforts have been shown to 
prolong survival (10, 25, 26). The various treatment options and approaches for patients 
with SBS/IF are described below. 
 
Nutritional Therapy 
Much of the long-term management of fluid, electrolyte, and nutritional balance in 
patients with SBS/IF is achieved through a combination of oral nutrition, enteral 
nutrition, and PN. Nutritional needs are heavily dictated by which segments and what 





frequent meals high in fat, soluble fiber, and complex carbohydrates are recommended. 
Isotonic oral rehydration solutions (ORS) make use of the sodium-glucose cotransporter 
in the small bowel and are therefore especially important in these patients for fluid 
uptake and hydration (16, 26). In contrast, those individuals with intact colon are better 
suited to diets of limited fat content and greater proportions of complex carbohydrates; 
ORS are not necessary. Similarly, maintenance of vitamin B12 and methylmalonic acid 
levels is especially important in cases of resection of the distal ileum (16, 26). It is 
suggested that all patients with SBS take calcium, magnesium, and zinc supplements in 
addition to a daily multivitamin. In those not receiving PN, supplementation with the 
fat-soluble vitamins A, D, E, and K is encouraged (4, 16, 26). 
Safe PN is life-saving for patients with SBS/IF. Recent advances in our 
understanding of the relationship between PN and IFALD have shed some light on how 
to best provide PN safely. PN preparations containing soy-derived omega-6 fatty acids 
may play a role in IFALD. There have been preliminary reports to suggest that, in fact, 
fish oil-based omega-3 fatty acids may be beneficial in pediatric IFALD (6, 11). For 
example, Smoflipid (Fresenius Kabi), an intravenous fat emulsion containing fish, soy, 
olive, and medium-chain oils, was approved in 2016 for adults. Thus far, one pediatric 
randomized controlled trial has shown promising results: lower levels of conjugated 
bilirubin were found in infants treated with Smoflipid as compared to those treated with 
the soy-derived Intralipid (Fresenius Kabi) (6, 27). Further studies are needed, however, 
as laboratory markers of cholestasis do not always correlate with liver histology (6). 
Early enteral nutrition, whether via nasogastric/gastrostromy tube or by mouth, 
has been shown to promote intestinal absorption and adaptation; the ability to wean 





16). Ultimately, the ideal goal in patients with SBS/IF is enteral autonomy: growth and 
maintenance of nutrition status and liver function, preferably without PN (4). 
 
Surgical Therapy 
Surgical procedures are a cornerstone of the management of patients with SBS. The 
spectrum of available options includes the placement of central venous catheters to 
deliver fluids and PN, as well as the insertion of gastrostomy, gastrojejunostomy, or 
jejunostomy devices to facilitate continuous feedings and enteral nutrition (4, 6). Other 
patients may be appropriate candidates for longitudinal intestinal lengthening and 
tailoring (LILT), the serial transverse enteroplasty (STEP) procedure, or even intestinal 
transplantation. 
LILT was first introduced by Bianchi in 1980 (28). In the operation, the 
mesenteric vasculature is carefully preserved before the intestinal lumen is divided 
longitudinally in half with a gastrointestinal anastomosis (GIA) stapler. The two 
“hemiloops” of bowel are then anastomosed end-to-end, to essentially double the 
intestinal length (28). 
In the STEP procedure, the GIA stapler is serially used on alternating sides of the 
bowel, to create a zig-zag pattern. This method, which effectively narrows the bowel 
lumen while increasing intestinal length, preserves the vasculature, avoids enterotomies 
and anastomoses, and has been very successful (4, 29). 
Lastly, intestinal transplantation is an option for patients with “permanent” IF 
and critically serious PN complications: portal hypertension, impaired liver synthetic 
function, numerous central line infections, multiple instances of central venous 





approximately 50%, the one-year rates range from 80% to over 90%, far surpassing the 
60% of patients who survive five years on PN. Taking into consideration the high cost of 
PN, the value of intestinal transplantation in patients with permanent IF has become a 
matter of small debate (4). 
 
Pharmacotherapy 
The pharmacotherapy for SBS is largely limited to antisecretory and antimotility agents, 
as well as agents thought to promote intestinal growth and adaptation (12, 16, 26). 
Therapies targeting the gastric hypersecretion and secretory diarrhea that commonly ail 
patients with SBS include H2 blockers, proton-pump inhibitors, octreotide, 
cholestyramine, and the α2 agonist clonidine (4, 16, 26, 30-32). Similarly, antimotility 
medications such as loperamide, diphenoxylate/atropine, and certain opioids (codeine, 
opium tincture) have been shown to provide relief and help slow intestinal transit time 
(4, 16, 26). Unfortunately, these therapies have been primarily studied in adult SBS/IF 
patients; few have been explored in the pediatric population (6). 
Various other treatments have found utility in SBS. Broad-spectrum antibiotics, 
namely metronidazole, ciprofloxacin, and rifaximin, and probiotics have been used to 
combat small intestinal bacterial overgrowth (6, 16, 26). Ursodeoxycholic acid has also 
been effective in managing PN-associated cholestasis (4). 
One of the most notable pharmacotherapies for SBS available to date, however, is 
teduglutide, a glucagon-like peptide 2 analog. Administered via subcutaneous injection, 
it is currently approved for adult PN-dependent patients, but its propensity to stimulate 
the development of neoplasms has limited its use, especially in children (33). Thus, there 





area and absorptive function. For these reasons, new therapies that specifically and 
actively increase intestinal mucosal surface area, especially those administered orally, 
are desperately needed for children with severe SBS and IF. 
 
1.2. Serotonin and the Enteric Nervous System 
The neural crest gives rise to the enteric nervous system (ENS), which is a complex 
network of nerves found in the bowel wall extending from the esophagus to the anus. It 
is comprised of the myenteric and submucosal plexuses. The ENS notably functions and 
carries out reflexes independently of the central nervous system (CNS), but nevertheless, 
there is much interaction between the two nervous systems (34, 35). 
Indeed, one of the most well-known neurotransmitters in the brain, serotonin or 
5-hydroxytryptamine (5-HT), is also found in great abundance in the ENS. Its receptors 
and functions are found in every major organ system in the body, but in fact, an 
overwhelming 95% of the body’s 5-HT stores are found in the gastrointestinal (GI) 
system (35, 36). Serotonin’s synthesis occurs in enterochromaffin cells of the intestinal 
mucosa, where it then acts on extrinsic nerves involved in sensory neurotransmission to 
the CNS, 5-HT3 receptors of intrinsic primary afferent neurons (IPANs) in the myenteric 
plexus, and 5-HT1P receptors of IPANs in the submucosal plexus. Aided by 5-HT4, 
submucosal nerves release acetylcholine and calcitonin gene-related peptide (CGRP), 
which ultimately influence intestinal secretion and peristalsis. Myenteric IPANs release 
only acetylcholine and have been implicated in giant migrating contractions (35). There 
has also been evidence to show that serotonin plays a role in bone formation and liver 





 The ubiquity of 5-HT in the bowel and the ability of the ENS to control multiple 
aspects of GI function drove us to explore serotonin’s potential as an intestinal mucosal 
growth factor, with the ultimate goal of targeting the 5-HT signaling system as a therapy 
for SBS/IF. 
 
1.2.1. Previous Work 
Due to the distribution of serotonin and the availability of pharmacologic agents that 
have been designed to alter its physiology, we have focused on its action in the bowel. 
Our laboratory has shown previously, via both genetic knock-out models and 
pharmacologic inhibition, that neuronal serotonin induces intestinal mucosal growth 
(40). In these experiments, wild-type (WT) mice receiving selective serotonin reuptake 
inhibitors (SSRIs) parenterally via intraperitoneally implanted osmotic micropumps 
were found to have increased villus height (VH), crypt depth (CD), and enterocyte 
proliferation, by day 7 of treatment (40). We therefore aimed to extend these findings to 
allow for a more translational approach and hypothesized that enteral dosing of the 
SSRI citalopram would also induce intestinal mucosal growth, thus allowing for therapy 










1. To develop an enteral route of administering SSRI to mice in a reliable, safe, and 
palatable manner. 




1. The enteral administration of citalopram is strongly associated with increases in 
VH and CD in WT mice in a dose- and time-dependent fashion, when compared 








This protocol (#2016-11567) was approved by the Yale University Institutional Animal 
Care & Use Committee. 
 
3.1. Author Contributions 
All data acquisition (animal experiments, intestinal resection, morphometric 
measurements), statistical analysis, and data interpretation were completed by LZ. All 
authors (LZ, CJG, RAC) participated in the conception and design of the study as well as 
drafting and critical revision of the associated manuscript. 
 
3.2. Vehicle of SSRI Administration 
Our experiments were conducted in two phases. In the first, we opted to use peanut 
butter (PB) as the vehicle of drug delivery, in lieu of more stressful approaches such as 
oral gavage, and adapted our methods from previously described studies (41, 42). For 
our second phase of longer-term studies, we explored the administration of SSRI in 
drinking water. Both methods of SSRI administration are described below in greater 
detail. 
 
3.2.1. Peanut Butter Pellets 
Peanut Delight creamy PB (Aldi Inc., Batavia, IL, USA) was heated in an 850-watt 
microwave oven for 40-80 seconds until a thick liquid consistency was achieved. PB 
pellets with SSRI were prepared by thoroughly mixing citalopram hydrobromide 





10, 25, 50, or 100 mg/kg per 0.2 mL pellet into the PB. All pellets were aliquoted onto a 
Parafilm membrane using a small-volume syringe, then stored for use at -20°C. Fresh 
pellets were made every 4-5 days (Figure 1). Mice underwent a 7-day habituation period 
and then either a 7-, 14-, or 21-day experimental period. Throughout both phases, they 
were transferred temporarily to individual cages for the duration of the administration 
of the PB pellet. 
 
 
Figure 1. Peanut Butter (PB) Pellets. 
 
Habituation Period 
Every day for seven consecutive days, mice were presented with a 0.2 mL plain PB pellet 
that was placed on the nozzle of a water bottle. Mice did not immediately take to the PB 
pellet—perhaps due to its novelty—but as described in the literature, by day 7, they 
consumed it within minutes of presentation (41). 
 
Experimental Period 
One cohort of mice was fed PB pellets containing either 10 mg/kg, 50 mg/kg, or 100 
mg/kg citalopram, or plain PB pellets, once daily for 7 days. Significant difficulty was 
noted in ensuring that mice consumed the PB pellets with the higher doses of 





experiments. The second cohort was provided with pellets containing 25 mg/kg 
citalopram or plain PB pellets, once daily for 14 or 21 days. Pellets were again presented 
via water bottle nozzle and mice consumed these without difficulty. 
 
3.2.2. Drinking Water 
In order to more feasibly conduct longer term studies, we used drinking water as a 
vehicle of delivery of enteral SSRI. Given that mice take in anywhere between 2.12 mL 
and 6.7 mL of water per day, we assumed a daily average of 4 mL water (43, 44). 
Solutions of citalopram hydrobromide were prepared at concentrations of 10, 25, or 50 
mg/kg/day; dissolved into tap water by vortexing; and administered for 2, 3, 6, or 8 
weeks, or for 6 weeks immediately followed by 2 weeks of plain tap water. Opaque 
water bottles were used throughout all drinking water experiments in order to protect 
both drug and water from light, and fresh solutions were made weekly. 
 
3.3. Animals 
The average mouse lives for 1 to 3 years. Weaning occurs at age 3-4 weeks, and puberty 
at 4-7 weeks (43). We chose to utilize 6- to 10-week old mice as our model of the 
pediatric age group. 
Wild-type C57BL/6 mice were housed with access to standard chow and water 
ad libitum under standard 12 hour light/dark conditions in the Yale Animal Resource 
Center. For the entire duration of our experiments, mice were weighed daily (PB pellet 
studies) or weekly (drinking water studies). One mouse, of all animals studied in both 
the PB pellet and drinking water studies, was euthanized due to illness prior to the end 





all animals and subsequent tissue specimens and histologic slides were each identified 
by a nondescript cage number and ear clipping; the treatment condition assigned to each 
mouse was referred to only when absolutely necessary during treatment (PB pellet or 
water bottle) administration. 
 
3.4. Histology 
At the conclusion of the experimental period, mice were euthanized by CO2 
asphyxiation. A midline laparotomy was performed, and the small intestine was 
isolated, harvested, and gently flushed free of stool with 10% neutral buffered formalin 
(NBF). Two-centimeter segments of the distal ileum were fixed overnight at room 
temperature in 10% NBF. We enlisted the help of Yale Pathology Tissue Services to 
paraffin-embed and section the tissue specimens into thin slices for staining with 
hematoxylin and eosin. Lastly, the slides were visualized under standard brightfield 
microscopy at 20x magnification (Zeiss Axio Imager.M1, Oberkochen, Germany). 
 
3.5. Measurements and Calculations 
Using ImageJ (NIH, Bethesda, MD, USA), we measured VH, CD, villus width (VW), and 
crypt width (CW), as defined by the crypt-villus junction (Figure 2). 
As detailed above, investigators carrying out the measurements were blind to the 
experimental treatment condition corresponding to each histologic slide. Intestinal villi 
and crypts selected for measurement were unique and fully intact with the entire length 
of the central lacteal or crypt lumen clearly visible. We did not measure villi or crypts 
















Figure 2 demonstrates a representative villus unit. For each villus unit with 
corresponding values for VH, VW, CD, and CW, we used a previously described 
mathematical approximation of intestinal mucosal surface area (MSA) to calculate MSA 
per mm2 (46): 





















2   (46) 
All measured and calculated data were compared using Student’s t-test. Statistical 
significance was defined when p <0.05. 
  
Figure 2. Example Villus Unit with 
Corresponding Villus and Crypt. 
VH = villus height, VW = villus 









Treatment with oral citalopram caused no obvious adverse effects. SSRI-treated animals 
experienced similar patterns of weight gain—and namely, did not experience weight 
loss—when compared to control animals. 
 
4.1. Peanut Butter Pellets 
Seven days of oral citalopram given at 10, 50, or 100 mg/kg/day resulted in virtually no 
differences compared to controls treated with PB pellets alone in three of the measured 
parameters, VH, VW, and CD, regardless of citalopram dose; the one exception was an 
increase in VW (p = 0.0093) in mice receiving 10 mg/kg/day. At all three doses, 
however, CW decreased significantly (p-values ranging from 0.0002 to <0.0001), likely 
contributing to the increases in MSA (p-values from 0.0578 to 0.0006) (Table 1). 
 
Table 1. Measured Mucosal Parameters after the Enteral Administration of 
Citalopram in Peanut Butter (PB) Pellets for 7 Days. 
 Vehicle (n)  10 mg/kg/day (n) p-value  50 mg/kg/day (n) p-value  100 mg/kg/day (n) p-value 
VH (μm) 209.7 ± 5.8 (40)  210.6 ± 2.6 (103) 0.8703  217.9 ± 4.4 (34) 0.2774  198.7 ± 3.4 (63) 0.0829 
VW (μm) 58.8 ± 1.7 (40)  63.8 ± 0.9 (103) 0.0093  57.0 ± 2.2 (34) 0.5119  62.2 ± 1.2 (63) 0.1124 
CD (μm) 69.8 ± 8.0 (6)  82.0 ± 2.4 (52) 0.1138  74.5 ± 2.6 (22) 0.4718  70.9 ± 3.0 (26) 0.8855 
CW (μm) 46.4 ± 2.2 (6)  33.0 ± 0.7 (52) <0.0001  36.3 ± 1.0 (22) 0.0002  35.2 ± 0.8 (26) <0.0001 
MSA (per mm2) 5.2 ± 0.1 (6)  6.4 ± 0.1 (52) 0.0045  6.3 ± 0.1 (22) 0.0006  5.8 ± 0.2 (26) 0.0578 
VH = villus height, VW = villus width, CD = crypt depth, CW = crypt width, MSA = 
mucosal surface area 
 
After 14 days of treatment, enteral citalopram at 25 mg/kg/day significantly 
increased VH and VW compared to controls, by approximately 12.3% (p <0.0001) and 





decreased by 12.7% (p = 0.0020). Overall, calculated ileal MSA per mm2 increased by 
22% from 5.0 ± 0.2 to 6.1 ± 0.1 (p = 0.0007) (Figure 3). 
Significant differences in VH, VW (data not shown), and CD were no longer seen 
by day 21 of enteral citalopram at 25 mg/kg/day. Crypt width decreased by 37.7% (p 
<0.0001), with a concurrent increase in MSA of 36.8% (p <0.0001) (Figure 3). 
 
Figure 3. Measured Mucosal Parameters after the Enteral Administration of 
Citalopram in Peanut Butter (PB) Pellets for 14 or 21 Days. 
Citalopram was dosed at 25 mg/kg/day. Panels A-D show VH, CD, CW, and MSA, 
respectively. VH = villus height, CD = crypt depth, CW = crypt width, MSA = mucosal 






4.2. Drinking Water 
Citalopram was administered in drinking water at 10, 25, or 50 mg/kg per day, for 2, 3, 
6, or 8 weeks; Figure 4 depicts MSA per square millimeter under these experimental 
conditions. Notably, with one exception at week 2 (Table 2), no differences in MSA were 
seen until week 6 when comparing controls and the three treatment doses. At the 6-
week and 8-week time points, mucosal surface was consistently greater in controls than 
in any animals receiving enteral citalopram (p <0.0001 across all doses at both time 
points). 
 
Figure 4. Muco sal Surface Area (MSA) after Long-Term Enteral Administration of 
Citalopram. 
 
In mice that received citalopram-treated drinking water of 10 or 50 mg/kg/day 
for 2 weeks, VH decreased from controls by 7.3% (p = 0.0016) and 13.7% (p <0.0001), 
respectively, while in those that received 25 mg/kg/day citalopram, VH remained 
statistically similar (p = 0.6394). CD was significantly reduced among all animals given 





MSA per mm2 for this treatment duration, a reduction from 5.5 ± 0.2 in controls to 4.6 ± 
0.1 (p = 0.0006), occurred at a drug concentration of 50 mg/kg/day. 
 By 3 weeks, citalopram-treated villi were taller than controls by roughly 32.9% 
(10 mg/kg/day, p <0.0001), 28.3% (25 mg/kg/day, p <0.0001), and 13.8% (50 
mg/kg/day, p <0.0001). No differences, however, were seen in CW (p = 0.8309, p = 
0.1231, and p = 0.1394, corresponding respectively to 10, 25, and 50 mg/kg/day 
citalopram) or MSA (p = 0.2053, p = 0.1628, and p = 0.3609). 
 VH was increased from controls by 3.1% after treatment with 10 mg/kg/day 
citalopram for 6 weeks (p = 0.0308); dosing at 50 mg/kg/day resulted in an 11.5% 
increase (p <0.0001). A 4.4% reduction in height was seen with the 25 mg/kg/day dose 
(p = 0.0057) (Figure 5). Furthermore, after 6 weeks, all villi and crypts of citalopram-
treated mice were significantly wider than controls, while crypt depth was decreased. 
As noted above, calculated mucosal surface by week 6 in animals of the three treatment 
doses was 20.6%, 25.4%, and 14.3% less than that of controls (corresponding to 10, 25, 
and 50 mg/kg/day citalopram, respectively; p <0.0001 across all three doses). 
 
Figure 5. Villus Height (VH) after Administration of Citalopram in Drinking Water. 
Panels A and B correspond to 6- and 8-week treatments, respectively. 





The time point at 8 weeks was notable for shorter and wider villi in all 
citalopram-treated animals when compared to controls (p <0.0001 across all three doses, 
for both VH and VW) (Figure 5). Again, MSA per mm2 in animals receiving 10, 25, or 50 
mg/kg/day citalopram in water for 8 weeks was decreased from controls by 25.4%, 
28.2%, and 26.8%, respectively (p <0.0001 across all three doses). 
Drug withdrawal for 2 weeks following 6 weeks of citalopram treatment also 
showed villi that were significantly shorter and wider than controls. While CW was 
statistically similar between control and all treatment groups in this cohort, MSA per 
mm2 in treated animals was reduced from controls by 21.1%, 33.8%, and 31.0% 
(respectively 10, 25, and 50 mg/kg/day citalopram; p <0.0001 across all three doses). 
Mean values for VH, VW, CD, CW, and MSA under all experimental doses and 






Table 2. Measured Mucosal Parameters after the Enteral Administration of 
Citalopram in Drinking Water. 
Treatment for 2 Weeks 
 Vehicle (n)  10 mg/kg/day (n) p-value  25 mg/kg/day (n) p-value  50 mg/kg/day (n) p-value 
VH (μm) 206.3 ± 6.3 (30)  191.2 ± 1.3 (351) 0.0016  209.3 ± 2.4 (174) 0.6394  178.0 ± 1.6 (295) <0.0001 
VW (μm) 68.8 ± 1.6 (30)  65.3 ± 0.5 (351) 0.0616  63.5 ± 0.6 (174) 0.0012  65.5 ± 0.6 (295) 0.0707 
CD (μm) 97.0 ± 2.2 (18)  75.2 ± 2.1 (116) <0.0001  67.8 ± 3.6 (49) <0.0001  63.1 ± 1.1 (103) <0.0001 
CW (μm) 36.4 ± 1.1 (18)  39.3 ± 0.8 (116) 0.1362  41.3 ± 0.7 (49) 0.0004  43.0 ± 0.5 (103) <0.0001 
MSA (per mm2) 5.5 ± 0.2 (8)  5.3 ± 0.1 (97) 0.5155  5.6 ± 0.1 (52) 0.9475  4.6 ± 0.1 (71) 0.0006 
 
Treatment for 3 Weeks 
 Vehicle (n)  10 mg/kg/day (n) p-value  25 mg/kg/day (n) p-value  50 mg/kg/day (n) p-value 
VH (μm) 153.9 ± 6.7 (14)  204.5 ± 1.6 (234) <0.0001  197.5 ± 2.0 (203) <0.0001  175.2 ± 1.0 (342) <0.0001 
VW (μm) 73.5 ± 3.2 (14)  70.2 ± 0.8 (234) 0.3306  65.4 ± 0.7 (203) 0.0064  64.4 ± 0.5 (342) 0.0002 
CD (μm) 89.0 ± 4.1 (6)  76.6 ± 1.8 (100) 0.1027  69.8 ± 2.5 (68) 0.0278  53.3 ± 0.9 (89) <0.0001 
CW (μm) 42.1 ± 2.8 (6)  42.8 ± 0.8 (100) 0.8309  38.0 ± 0.7 (68) 0.1231  39.0 ± 0.5 (89) 0.1394 
MSA (per mm2) 4.4 ± 0.3 (2)  5.2 ± 0.1 (60) 0.2053  5.4 ± 0.1 (53) 0.1628  4.8 ± 0.1 (79) 0.3609 
 
Treatment for 6 Weeks 
 Vehicle (n)  10 mg/kg/day (n) p-value  25 mg/kg/day (n) p-value  50 mg/kg/day (n) p-value 
VH (μm) 182.5 ± 2.5 (125)  188.1 ± 1.3 (285) 0.0308  174.5 ± 1.6 (286) 0.0057  203.4 ± 1.7 (193) <0.0001 
VW (μm) 52.8 ± 0.7 (125)  63.7 ± 0.5 (285) <0.0001  67.8 ± 0.5 (286) <0.0001  62.9 ± 0.7 (193) <0.0001 
CD (μm) 68.8 ± 1.4 (68)  61.2 ± 1.3 (82) 0.0001  62.3 ± 1.2 (96) 0.0006  62.1 ± 1.7 (77) 0.0032 
CW (μm) 29.4 ± 0.6 (68)  40.9 ± 0.7 (82) <0.0001  41.6 ± 0.5 (96) <0.0001  41.5 ± 0.6 (77) <0.0001 
MSA (per mm2) 6.3 ± 0.2 (49)  5.0 ± 0.1 (52) <0.0001  4.7 ± 0.1 (70) <0.0001  5.4 ± 0.1 (44) <0.0001 
 
Treatment for 8 Weeks 
 Vehicle (n)  10 mg/kg/day (n) p-value  25 mg/kg/day (n) p-value  50 mg/kg/day (n) p-value 
VH (μm) 239.5 ± 7.1 (39)  207.4 ± 2.3 (221) <0.0001  206.6 ± 2.3 (224) <0.0001  190.5 ± 2.4 (163) <0.0001 
VW (μm) 56.2 ± 1.8 (39)  66.5 ± 0.7 (221) <0.0001  67.2 ± 0.8 (224) <0.0001  63.4 ± 0.6 (163) <0.0001 
CD (μm) 69.3 ± 4.0 (9)  71.5 ± 1.2 (102) 0.5897  68.9 ± 1.6 (80) 0.9353  54.9 ± 0.9 (68) <0.0001 
CW (μm) 39.7 ± 2.1 (9)  42.7 ± 0.5 (102) 0.0774  44.4 ± 0.7 (80) 0.0451  40.0 ± 0.7 (68) 0.8856 
MSA (per mm2) 7.1 ± 0.4 (12)  5.3 ± 0.1 (60) <0.0001  5.1 ± 0.1 (49) <0.0001  5.2 ± 0.1 (46) <0.0001 
 
Treatment for 6 Weeks + Withdrawal for 2 Weeks 
 Vehicle (n)  10 mg/kg/day (n) p-value  25 mg/kg/day (n) p-value  50 mg/kg/day (n) p-value 
VH (μm) 239.5 ± 7.1 (39)  220.3 ± 2.5 (142) 0.0017  176.4 ± 2.5 (293) <0.0001  181.2 ± 2.1 (321) <0.0001 
VW (μm) 56.2 ± 1.8 (39)  67.8 ± 0.9 (142) <0.0001  70.2 ± 0.6 (293) <0.0001  66.0 ± 0.7 (321) <0.0001 
CD (μm) 69.3 ± 4.0 (9)  72.3 ± 1.2 (72) 0.4099  67.1 ± 2.1 (98) 0.7645  60.7 ± 1.3 (84) 0.0461 
CW (μm) 39.7 ± 2.1 (9)  43.6 ± 0.7 (72) 0.0777  42.3 ± 0.6 (98) 0.1986  42.6 ± 0.9 (84) 0.2915 








In previous work, we studied VH and CD, among other parameters, after parenteral 
administration of citalopram at 25 mg/kg/day. By 7 and 14 days of treatment, VH was 
increased from controls by roughly 15% and 12%, respectively, and CD by 7% and 18% 
(40). That same investigation examined genetic mouse models where the serotonin 
reuptake transporter is absent (SERTKO), and found an increase in VH by 
approximately 40% compared to WT mice (40). 
Building on this past work, in the first phase of the current study, we delivered 
citalopram via PB pellets to WT mice for 7, 14, or 21 days, at varying doses. No changes 
in either VH or CD were seen when citalopram was given for 7 days, at 3 doses ranging 
from 10 to 100 mg/kg/day. On the other hand, fourteen days of citalopram in PB pellets 
at 25 mg/kg/day caused a statistically significant increase in VH of approximately 12%, 
though CD remained unchanged compared to controls. The slower changes seen with 
this enteral route of administration of SSRI are most likely pharmacokinetic in nature 
and secondary to first-pass metabolism, which is not involved when the drug is given 
parenterally (47, 48). Our findings also suggest that changes in CD may be slowest to 
occur, if at all, of all measured parameters. 
 In the second phase of our study, citalopram was delivered in drinking water for 
2, 3, 6, or 8 weeks, as well as for 6 weeks immediately followed by a 2-week washout 
period. In contrast to the findings seen with citalopram in PB pellets, dosing of the drug 
in drinking water resulted in taller villi by three, not two, weeks. As we expected both 
PB pellets and drinking water to be comparable enteral routes of administration, this 





bolus-style drug delivery of PB pellets and relatively continuous drug supply of 
drinking water. Moreover, although mice had unlimited access to their water treatment, 
we had assumed an average daily water intake of 4 mL, and they were otherwise 
relatively unmonitored in the animal housing facility. It is very possible that the 
citalopram water was poorly palatable, that mice drank less water than assumed, and 
that steady-state drug levels were low. Overall, we did not monitor daily water intake or 
citalopram levels in the body at any point during the study. 
Another unexpected finding was that all doses and durations of the citalopram-
treated water showed either no difference in MSA from controls, or in some cases, a 
significant decrease. Most notably, mucosal surface in the control group progressively 
increased from week 3 to week 6 to week 8, as the animal grew in age and size. This 
trend was not seen in any of the experimental groups, raising the question of an 
inhibitory effect with chronic treatment. By comparison, 25 mg/kg/day citalopram in 
PB pellets increased mucosal surface per mm2 by 21.8% by week 2 and by 36.8% by week 
3. It is perhaps worth noting, however, that VH, VW, and CD, were statistically similar 
between the PB experimental and control groups at the 3-week mark; narrower crypts, 
and not taller, thinner villi or deeper crypts, were the most likely driver of the increases 
in MSA in that cohort. 
One group of mice received citalopram in drinking water for six weeks, and then 
was immediately transitioned to plain tap water for two weeks. Comparison with the 8-
week control group showed shorter, wider villi, corresponding to a decreased MSA per 
mm2. These trends were identical to those observed in the 8-week experimental group, 





plateau at the 6- to 8-week mark, or that it may simply take longer than two weeks for 
the mucosa to return to its starting baseline. 
With respect to currently available medical therapies for SBS, teduglutide 
remains the only one approved for use in adult disease. In the study demonstrating 
efficacy of this agent, mice injected with glucagon-like peptide 2 were found to have 
increases in VH, from controls, of approximately 25% by 6 days of treatment and 50% by 
10 days, with no significant differences in CD (49). By contrast, we found that 14 days of 
enteral citalopram resulted in a more modest increase in VH of 12.3%. Whether this is a 
mechanistic and/or pharmacokinetic phenomenon remains to be seen; nevertheless, the 
oral route of citalopram administration was associated with a concurrent increase in VW 
and decrease in CW, likely contributing to the 22% increase in calculated MSA. 
Many questions remain regarding the precise role that serotonin plays in the 
ENS in the maintenance of intestinal mucosa, as well as the implications of intestinal 
mucosal growth on intestinal function. While further work is needed to refine our 
current understanding of this complex signaling environment in the ENS, we have 
presented some data to demonstrate the potential efficacy of an orally administered SSRI 
to promote intestinal mucosal growth, especially in the short-term period. 
 
5.1. Future Directions 
Long-term parenteral studies would provide invaluable data to compare with the results 
presented here. Further avenues of investigation into the enteral route should include 
analysis of other segments of the small bowel, such as the jejunum, as well as other 
measures of intestinal mucosal growth, such as intestinal weight and the crypt 





may be a limiting factor, future work should also explore other methods of enteral 
delivery, such as oral gavage, to ensure that the drug is ingested fully and in the 
expected amounts. While we have preliminary data showing increased absorption of 
solutes and nutrients in genetic mouse models, functional assays in the setting of enteral 
SSRI treatment would be of great interest. The ultimate goal would be to examine 
enteral SSRI administration in a large animal model of intestinal injury or after massive 
resection. 
 The population of patients who have short bowel syndrome and are also 
prescribed SSRIs for a mood disorder may prove to be enlightening. In 2014, Faye et al. 
examined the pharmacokinetics of oral and intravenous citalopram or escitalopram in 
eight such patients (50). Though the authors’ focus was primarily on steady-state 
concentrations and concentration-dose ratios (CDRs), they also included in their analysis 
such variables as frequency of PN, small bowel length, and percentage of intact colon. 
Patients required PN anywhere from 0 to 7 times per week, and their remaining lengths 
of small intestine ranged from 5 cm to 200 cm. A small intestinal length of less than 20 
cm was associated with poor absorption (low steady-state concentration and CDR), 
while patients with greater than 180 cm of small bowel remaining, or more than 80 cm 
small bowel and at least half their colon, had normal serum levels of drug (50). While 
this was a small study, it introduces a special group of patients who are highly relevant 
to the research question posed here. 
 
5.2. Limitations 
Though both plain and SSRI PB pellets were indistinguishable in appearance, 





citalopram were not as readily accepted by mice when presented as part of a PB pellet, 
and the final dose absorbed by each animal was difficult to control entirely when 
compared to a parenteral dosing regimen. Similarly, investigators were not blinded to 
the drug concentration when preparing, refilling, and administering citalopram 
solutions. 
Moreover, the sample sizes of the drinking water control groups (that is, no 
drug) were very small. Only one animal was studied per experimental condition, which 
therefore limited the number of intact villi and crypts that were candidates for 
measurement. Additionally, both male and female mice were used indiscriminately 
throughout the study, as well as mice anywhere from 6 to 10 weeks of age. Our study 
did not control or balance for sex, as recommended in 2014 by the National Institutes of 
Health’s “Policy on Sex as a Biological Variable” (51, 52). These potentially confounding 
factors, in addition to random variation itself, could have been mitigated with a more 
robust sample size. 
To truly isolate the effect of citalopram, it would have been ideal to measure villi 
and crypts before and after drug treatment from the same animal. Lastly, the equation 
we favored to estimate mucosal surface area is merely one of several mathematical 
models that have been proposed (46, 53, 54). 
 
5.3. Conclusions 
This year, 2018, marks 50 years since Wilmore and Dudrick first used parenteral 
nutrition to treat pediatric short bowel syndrome. Though we now have a great number 
more and a wider variety of treatment options for SBS and IF, PN remains fundamental 





Building on previous work on parenteral citalopram, we sought to investigate 
the effect of the enteral citalopram on intestinal mucosal morphometrics and surface 
area in WT mice, at a range of treatment doses and durations. In this study, we utilized 
both PB pellets and drinking water as vehicles to deliver our drug. Fourteen days of 
citalopram in PB pellets resulted in increased VH, VW, and ileal MSA, and the increased 
mucosal surface was sustained at day 21. Drinking water seemed to be less effective. VH 
in citalopram-treated animals was greater than controls by week 3, but this finding 
dissipated by weeks 6 and 8. MSA per mm2 in the treatment group, across all doses and 
durations, was statistically similar to or decreased from the control group. 
While the drinking water results were unexpected, much of the PB pellet data 
showed promise. Further studies would be invaluable for shedding light on the 
serotonin signaling system in the bowel, as well as on the potential for an orally and 









1. Gawande A. Better: A Surgeon's Notes on Performance. New York: Picador; 2007. 
2. Wilmore DW, and Dudrick SJ. Growth and development of an infant receiving 
all nutrients exclusively by vein. JAMA. 1968;203(10):860-4. 
3. Wales PW, and Christison-Lagay ER. Short bowel syndrome: epidemiology and 
etiology. Semin Pediatr Surg. 2010;19(1):3-9. 
4. Duro D, Kamin D, and Duggan C. Overview of pediatric short bowel syndrome. 
J Pediatr Gastroenterol Nutr. 2008;47:S33-S6. 
5. Spencer AU, Kovacevich D, McKinney-Barnett M, Hair D, Canham J, Maksym C, 
et al. Pediatric short-bowel syndrome: the cost of comprehensive care. Am J Clin 
Nutr. 2008;88(6):1552-9. 
6. Duggan CP, and Jaksic T. Pediatric intestinal failure. N Engl J Med. 
2017;377(7):666-75. 
7. Wales PW, de Silva N, Kim J, Lecce L, To T, and Moore A. Neonatal short bowel 
syndrome: population-based estimates of incidence and mortality rates. J Pediatr 
Surg. 2004;39(5):690-5. 
8. Cole CR, Hansen NI, Higgins RD, Ziegler TR, and Stoll BJ. Very low birth weight 
preterm infants with surgical short bowel syndrome: incidence, morbidity and 
mortality, and growth outcomes at 18 to 22 months. Pediatrics. 2008;122(3):e573. 
9. Cole CR, Hansen NI, Ziegler T, and Stoll BJ. Outcomes of low-birth-weight 
infants with surgical short bowel syndrome (Poster Abstract 45). North American 
Society of Pediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting. 
2005;41(4). 
10. Squires RH, Duggan C, Teitelbaum DH, Wales PW, Balint J, Venick R, et al. 
Natural history of pediatric intestinal failure: initial report from the pediatric 
intestinal failure consortium. The Journal of Pediatrics. 2012;161(4):723-8.e2. 
11. Carroll RE, Benedetti E, Schowalter JP, and Buchman AL. Management and 
complications of short bowel syndrome: an updated review. Current 
Gastroenterology Reports. 2016;18(7):40. 
12. O’Keefe SJD, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, and 
Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and 
overview. Clin Gastroenterol Hepatol. 2006;4(1):6-10. 
13. Messing B, Crenn P, Beau P, Boutron-Ruault MC, Rambaud J-C, and 
Matuchansky C. Long-term survival and parenteral nutrition dependence in 
adult patients with the short bowel syndrome. Gastroenterology. 1999;117(5):1043-
50. 
14. Lloyd DAJ, Vega R, Bassett P, Forbes A, and Gabe SM. Survival and dependence 
on home parenteral nutrition: experience over a 25-year period in a UK referral 





15. Buchman AL. The medical and surgical management of short bowel syndrome. 
Medscape General Medicine. 2004;6(2):12. 
16. Wall EA. An overview of short bowel syndrome management: adherence, 
adaptation, and practical recommendations. J Acad Nutr Diet. 2013;113(9):1200-8. 
17. Ardura MI, Lewis J, Tansmore JL, Harp PL, Dienhart MC, and Balint JP. Central 
catheter–associated bloodstream infection reduction with ethanol lock 
prophylaxis in pediatric intestinal failure: broadening quality improvement 
initiatives from hospital to home. JAMA Pediatrics. 2015;169(4):324-31. 
18. Oliveira C, Nasr A, Brindle M, and Wales PW. Ethanol locks to prevent catheter-
related bloodstream infections in parenteral nutrition: a meta-analysis. Pediatrics. 
2012;129(2):318. 
19. Mermel LA, and Alang N. Adverse effects associated with ethanol catheter lock 
solutions: a systematic review. J Antimicrob Chemother. 2014;69(10):2611-9. 
20. Pironi L, Morselli Labate AM, Pertkiewicz M, Przedlacki J, Tjellesen L, Staun M, 
et al. Prevalence of bone disease in patients on home parenteral nutrition. Clin 
Nutr. 2002;21(4):289-96. 
21. Btaiche IF, and Khalidi N. Parenteral nutrition-associated liver complications in 
children. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 
2002;22(2):188-211. 
22. Buchman A. Total parenteral nutrition-associated liver disease. Journal of 
Parenteral and Enteral Nutrition. 2002;26(5_suppl):S43-S8. 
23. Kelly DA. Intestinal failure–associated liver disease: what do we know today? 
Gastroenterology. 2006;130(2, Supplement):S70-S7. 
24. Quirós-Tejeira RE, Ament ME, Reyen L, Herzog F, Merjanian M, Olivares-
Serrano N, et al. Long-term parenteral nutritional support and intestinal 
adaptation in children with short bowel syndrome: a 25-year experience. The 
Journal of Pediatrics. 2004;145(2):157-63. 
25. Modi BP, Langer M, Ching YA, Valim C, Waterford SD, Iglesias J, et al. 
Improved survival in a multidisciplinary short bowel syndrome program. J 
Pediatr Surg. 2008;43(1):20-4. 
26. Parekh NR, and Steiger E. Short bowel syndrome. Current Treatment Options in 
Gastroenterology. 2008;10(1):10. 
27. Diamond IR, Grant RC, Pencharz PB, de Silva N, Feldman BM, Fitzgerald P, et al. 
Preventing the progression of intestinal failure-associated liver disease in infants 
using a composite lipid emulsion: a pilot randomized controlled trial of 
SMOFlipid. Journal of Parenteral and Enteral Nutrition. 2017;41(5):866-77. 
28. Bianchi A. Intestinal loop lengthening—a technique for increasing small 
intestinal length. J Pediatr Surg. 1980;15(2):145-51. 
29. Kim HB, Fauza D, Garza J, Oh J-T, Nurko S, and Jaksic T. Serial transverse 






30. Rubinoff MJ, Piccione PR, and Holt PR. Clonidine prolongs human small 
intestine transit time: use of the lactulose-breath hydrogen test. Am J 
Gastroenterol. 1989;84(4):372-4. 
31. McDoniel K, Taylor B, Huey W, Eiden K, Everett S, Fleshman J, et al. Use of 
clonidine to decrease intestinal fluid losses in patients with high-output short-
bowel syndrome. Journal of Parenteral and Enteral Nutrition. 2004;28(4):265-8. 
32. Buchman AL, Fryer J, Wallin A, Ahn CW, Polensky S, and Zaremba K. Clonidine 
reduces diarrhea and sodium loss in patients with proximal jejunostomy: a 
controlled study. Journal of Parenteral and Enteral Nutrition. 2006;30(6):487-91. 
33. Burness CB, and McCormack PL. Teduglutide: a review of its use in the 
treatment of patients with short bowel syndrome. Drugs. 2013;73(9):935-47. 
34. Gershon MD. In: Holschneider AM, and Puri P eds. Hirschsprung's Disease and 
Allied Disorders. Springer, Berlin, Heidelberg; 2008:21-49. 
35. Gershon MD, and Tack J. The serotonin signaling system: from basic 
understanding to drug development for functional GI disorders. Gastroenterology. 
2007;132(1):397-414. 
36. Berger M, Gray JA, and Roth BL. The expanded biology of serotonin. Annu Rev 
Med. 2009;60(1):355-66. 
37. Gershon MD. 5-hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr 
Opin Endocrinol Diabetes Obes. 2013;20(1):14-21. 
38. Liu M-T, Kuan Y-H, Wang J, Hen R, and Gershon MD. 5-HT4 receptor-mediated 
neuroprotection and neurogenesis in the enteric nervous system of adult mice. J 
Neurosci. 2009;29(31):9683-99. 
39. Greig CJ, Gandotra N, Tackett JJ, Bamdad MC, and Cowles RA. Enhanced 
serotonin signaling increases intestinal neuroplasticity. J Surg Res. 
2016;206(1):151-8. 
40. Gross ER, Gershon MD, Margolis KG, Gertsberg ZV, and Cowles RA. Neuronal 
serotonin regulates growth of the intestinal mucosa in mice. Gastroenterology. 
2012;143(2):408-17.e2. 
41. Gonzales C, Zaleska MM, Riddell DR, Atchison KP, Robshaw A, Zhou H, et al. 
Alternative method of oral administration by peanut butter pellet formulation 
results in target engagement of BACE1 and attenuation of gavage-induced stress 
responses in mice. Pharmacol Biochem Behav. 2014;126:28-35. 
42. Walker MK, Boberg JR, Walsh MT, Wolf V, Trujillo A, Duke MS, et al. A less 
stressful alternative to oral gavage for pharmacological and toxicological studies 
in mice. Toxicol Appl Pharmacol. 2012;260(1):65-9. 
43. Jacoby RO, Fox JG, and Davisson M. In: Fox J, Anderson L, Loew F, and Quimby 
F eds. Laboratory Animal Medicine. San Diego: Elsevier; 2002:35-120. 
44. Bernstein SE. In: Green EL ed. Biology of the Laboratory Mouse. New York: Dover 





45. Greig CJ, and Cowles RA. Improved capacity to evaluate changes in intestinal 
mucosal surface area using mathematical modeling. Microsc Res Tech. 2017:1-6. 
46. Kisielinski K, Willis S, Prescher A, Klosterhalfen B, and Schumpelick V. A simple 
new method to calculate small intestine absorptive surface in the rat. Clin Exp 
Med. 2002;2(3):131-5. 
47. Overø KF. Kinetics of citalopram in test animals; drug exposure in safety studies. 
Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):297-309. 
48. Overø KF, and Svendsen O. Hepatotoxicity of citalopram in rats and first-pass 
metabolism. Toxicol Aspects of Food Safety. 1978:177-80. 
49. Drucker DJ, Erlich P, Asa SL, and Brubaker PL. Induction of intestinal epithelial 
proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 
1996;93(15):7911-6. 
50. Faye E, Corcos O, Lancelin F, Declèves X, Bergmann J-F, Joly F, et al. 
Antidepressant agents in short bowel syndrome. Clin Ther. 2014;36(12):2029-
33.e3. 
51. Clayton JA, and Collins FS. NIH to balance sex in cell and animal studies. Nature. 
2014;509(7500):282-3. 
52. NIH Office of Research on Women's Health (ORWH). NIH Policy on Sex as a 
Biological Variable. https://orwh.od.nih.gov/research/sex-gender/nih-policy/.  
Accessed March 11, 2018. 
53. Fisher RB, and Parsons DS. The gradient of mucosal surface area in the small 
intestine of the rat. J Anat. 1950;84(Pt 3):272-82. 
54. Harris MS, Kennedy JG, Siegesmund KA, and Yorde DE. Relationship between 
distention and absorption in rat intestine. Gastroenterology. 1988;94(5):1164-71. 
55. Watterson B. The Complete Calvin and Hobbes. Kansas City, MO: Andrews McMeel 



























If you can’t control your peanut butter, you can’t expect to control your life. 
—Bill Watterson, The Complete Calvin and Hobbes (55) 
